Wenjuan Zheng

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · Journal of Clinical Oncology · 2015 · 381 citations · Full text

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Ying Cheng, Yun Fan, Yanqiu Zhao et al. · Journal of Thoracic Oncology · 2024 · 104 citations · Full text

Phase 3, Clinical Therapeutic, Pharmacology +7

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Caicun Zhou, Dingzhi Huang, Yun Fan et al. · Journal of Thoracic Oncology · 2022 · 97 citations · Full text

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial

Dongsheng Yue, Wenxiang Wang, Hongxu Liu et al. · The Lancet Respiratory Medicine · 2024 · 76 citations

Interim Analysis, Surgical Oncology, Neoadjuvant Chemotherapy +12

Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia

Lijuan Chen, Yaping Zhang, Wenjuan Zheng et al. · Leukemia Research · 2008 · 52 citations

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukemia +12